Clinical Trial Update: Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) [Phase 2]

View source ↗

Summary

Phase 2 trial of Paclitaxel Protein Bound with cisplatin, gemcitabine, and paricalcitol in pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Paclitaxel protein-bound (paclitaxel protein-bound)
• Paricalcitol (paricalcitol)

Snippet

Sponsor: HonorHealth Research Institute | Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED